Trending With Impact: Do Biomarkers of “Long COVID” Exist?

Listen to a blog summary of a trending research paper published by Aging (Aging-US) on February 16, 2022, entitled, “Elevated levels of serum CDCP1 in individuals recovering from severe COVID-19 disease.” _____ Among people who have been fortunate to recover from COVID-19, at least 40% had or have long-term lingering effects from this disease. Sometimes appearing months after recovering, these “long covid” effects can include (not limited to) fatigue, trouble sleeping, difficulty concentrating, joint or muscle pain, and respiratory issues, such as shortness of breath and chest pain. Researchers are still unsure as to whether or not lasting COVID-19 effects in the lungs are associated with the severity of disease at the time of infection. “Thus, prospective studies related to outcomes following recovery from COVID-19 might improve our understanding of this disease, its sequelae, and possible interventions to improve this situation.” Researchers—from Hospital Universitario San Pedro, Centro de Investigación Biomédica de La Rioja, Universidad de Córdoba, Hospital Universitario Reina Sofía, Hospital Costal de Sol, HCU Lozano Blesa, Hospital Universitario Marqués de Valdecilla, Unidad de Enfermedades Infecciosas, Hospital Universitario de Burgos, Vitro Laboratory, Instituto de Investigación-IdiPaz, and Universidad Rey Juan Carlos—conducted a new study aimed at identifying biomarkers of severe disease in patients after hospitalization for COVID-19. Their research paper was published by Aging (Aging-US) on February 16, 2022, and entitled, “Elevated levels of serum CDCP1 in individuals recovering from severe COVID-19 disease.” Full blog - https://aging-us.org/2022/03/trending-with-impact-do-biomarkers-of-long-covid-exist/ DOI - https://doi.org/10.18632/aging.203898 Corresponding Author - Jose-Ramon Blanco - jrblancoramos@gmail.com; https://orcid.org/0000-0002-4268-0150 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.203898 Keywords - biomarkers, CDCP1, recovery, COVID-19 About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at http://www.Aging-US.com​​ and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ Twitter - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/agingus​ LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Aging-US is published by Impact Journals, LLC: http://www.ImpactJournals.com​​ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM